METACHRONOUS BREAST AND RECTAL CANCERS: A CASE REPORT OF SUCCESSFULLY TREATED MULTIPLE PRIMARY MALIGNANT TUMORS

Main Article Content

Aliza Latif Aftab
Muhammad Imran Anwar
Muhammad Aamir Jameel
Aiza Latif Aftab

Keywords

metachronous, multiple primary malignant tumors (MPMTs), breast, rectum

Abstract

Genetic predispositions, host characteristics, environmental factors and higher cancer patient survival rates are all contributing to the rising prevalence of multiple primary malignant tumors (MPMTs). The global incidence of MPMTs is as high as 11.7%.


It is uncommon for MPMTs to affect both breast and rectum. Owing to the scarcity of available literature, there is lack of high-quality evidence that can guide clinicians on the management strategies of this complex oncological entity. In our study, we report a case of successfully treated metachronous tumors of the breast and rectum in a 71-year-old woman. The patient was first diagnosed with moderately differentiated invasive ductal carcinoma of left breast in 2019 for which she underwent modified radical mastectomy (MRM) followed by adjuvant chemo and radiotherapy. In 2021, she was diagnosed with adenocarcinoma of the rectum following multiple episodes of per rectal bleeding. The case was discussed in a multidisciplinary tumor board and after ruling out metastasis, a decision of neoadjuvant chemo-radio therapy followed by anterior resection of the tumor was made. The patient remains disease free so far.


In a nutshell, the likelihood of developing a primary second malignancy should always be kept in mind while evaluating a cancer patient. There are no specific guidelines for the management of MPMTs due to the paucity of available data. Therefore, it is imperative that both the patient and the clinician be vigilant for the emergence of new signs and symptoms after the occurrence of index primary malignancy.

Abstract 135 | pdf Downloads 64

References

1. Luo C, Wang L, Zhang Y, Lu M, Lu B, Cai J, et al. Advances in breast cancer screening modalities and status of global screening programs. Chronic Diseases and Translational Medicine. 2022 May 25;
2. Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. CA: A Cancer Journal for Clinicians. 2022 Jun 23;72(5).
3. Zhai C, Cai Y, Lou F, et al. Multiple Primary Malignant Tumors - A Clinical Analysis of 15,321 Patients with Malignancies at a Single Center in China. J Cancer 2018;9(16):2795-2801. doi:10.7150/jca.25482.
4. Karthikeyan VS, Sistla SC, Srinivasan R, Basu D, Panicker LC, Ali SM, et al. Metachronous Multiple Primary Malignant Neoplasms of the Stomach and the Breast: Report of Two Cases with Review of Literature. International Surgery [Internet]. 2014 Jan [cited 2019 Oct 4];99(1):52–5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897342/
5. Lv M, Zhang X, Shen Y, et al. Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors. Medicine (Baltimore) 2017;96: e6799.
6. Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, et al. Multiple primary tumours: challenges and approaches, a review. ESMO Open [Internet]. 2017;2(2):e000172. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519797/pdf/esmoopen-2017-000172.pdf
7. Warren S, Gates O. Multiple primary malignant tumors: A survey of the literature and statistical study. Am J Cancer. 1932;16:1358–414.
8. Chitwood H, Carey T. Managing the Patient With Multiple Primary Tumors. Journal of the Advanced Practitioner in Oncology [Internet]. 2023 Apr 1 [cited 2023 Dec 25];14(3):218–21. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184849/
9. ‌Mehdi I, Shah AH, Moona MS, Verma K, Abussa A, Elramih R, El-Hashmi H. Synchronous and metachronous malignant tumours expect the unexpected. J Pak Med Assoc. 2010 Nov;60(11):905-9. PMID: 21375191
10. Kim JY, Song HS. Metachronous Double Primary Cancer after Treatment of Breast Cancer. Cancer Research and Treatment : Official Journal of Korean Cancer Association [Internet]. 2015 Jan 1 [cited 2023 Dec 25];47(1):64–71. Available from: https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC4296850/
11. Osako T. How can we better distinguish metastatic tumors from primary tumors in the breast? Expert Review of Anticancer Therapy. 2021 Jun 28;1–4.
12. Schwarz RE, Klimstra DS, Turnbull AD. Metastatic breast cancer masquerading as gastrointestinal primary. The American Journal of Gastroenterology [Internet]. 1998 Jan 1 [cited 2023 Dec 29];93(1):111–4. Available from: https://pubmed.ncbi.nlm.nih.gov/9448188/
13. Abd ElLateef AAE, Mohamed AES, Elhakeem AA, Ahmed SF. Estrogen and Progesterone Expression in Colorectal Carcinoma: A Clinicopathological Study. Asian Pacific Journal of Cancer Prevention. 2020 Apr 1;21(4):1155–62.
14. Ordóñez NG. Value of GATA3 Immunostaining in Tumor Diagnosis. Advances In Anatomic Pathology. 2013 Sep;20(5):352–60.
15. Chaudhary P, Gupta S, Leekha N, Tandon R, Nandy M, De S. Pattern of occurrence and treatment outcome of second primary malignancies: A single center experience. South Asian Journal of Cancer [Internet]. 2017 [cited 2023 Dec 25];6(3):137–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615887/#ref4
16. Bin Y, Albandar MH, Alfaifi JA. Synchronous Colon and Breast Cancers: A Case Report of Multiple Primary Tumors. Cureus [Internet]. 2022 May 7; Available from: https://www. ncbi.nlm.nih.gov/pmc/articles/PMC9169435/

Most read articles by the same author(s)